Innovent’s PECONDLE Gains NMPA Approval as China’s First IL-23p19 Antibody
SAN FRANCISCO & SUZHOU, China — November 28, 2025. Innovent Biologics has announced that PECONDLE® (picankibart injection), a recombinant...
Autoimmune Disease
Advertisement
Lifordi Gains Major Investment to Advance ADC Autoimmune Therapy
Dateline Introduction Burlington, Massachusetts — November 18, 2025 — Lifordi Immunotherapeutics has announced a strategic investment from Sanofi Ventures,...
Exagen Inc. Showcases Autoimmune Diagnostic Leadership at Q4 2025 Conferences
Dateline — CARLSBAD, Calif., November 11, 2025:Exagen Inc. (Nasdaq: XGN), a leader in autoimmune diagnostics, has announced its participation...
IN8bio Reports Strong Q3 Progress in Gamma-Delta T Cell R&D
NEW YORK, November 6, 2025 — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell...
Kyverna Therapeutics Reports Breakthrough Phase 2 Results for KYV-101 in Myasthenia Gravis
Emeryville, California, October 29, 2025 — Kyverna Therapeutics Inc. (Nasdaq: KYTX) announced positive interim Phase 2 data from the...
Advertisements
Augurex Life Sciences Granted FDA Breakthrough Designation for SPINEstat
Vancouver, Canada, Oct. 28, 2025 — Augurex Life Sciences announced FDA Breakthrough Device Designation for its SPINEstat® blood test,...
Sanofi’s Wayrilz Approved in the U.S. as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
Advertisement
